Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.8
3.9
Journals
Biomedicines
Special Issues
New Insights in Gastric, Colorectal, and Pancreatic Cancer
share announcement

New Insights in Gastric, Colorectal, and Pancreatic Cancer

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: closed (31 May 2025) | Viewed by 3710

Special Issue Editor

Dr. John K. Triantafillidis

E-Mail Website
Guest Editor
Director IBD Unit, Metropolitan General Hospital, 15562 Holargos, Greece
Interests: nutrition; inflammatory bowel disease; malabsorption syndromes; chronic diarrhea; small and large bowel disorders; cancer epidemiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Gastric, colorectal and pancreatic cancer represent the most important malignant neoplasms of the digestive system in terms of frequency and clinical importance. Despite the apparent changes regarding their frequency, it seems that these neoplasms are appearing at younger ages. Over the last years, significant progress has been made in the etiology, diagnosis and therapeutic treatment (surgical and conservative) of these three malignant neoplasms, including their pre-cancerous conditions (polyps, IBD, etc.). Advances in conservative treatment are especially impressive. For example, immunotherapy of these cancers alone or in combination with systemic chemotherapy is the therapeutic strategy of the present and the future.

This Special Issue focuses on the recent data regarding these three neoplasms, intending to cover among others, the following topics:

  • Mechanisms of carcinogenesis;
  • Tumor cell biology;
  • Hereditary gastric, CRC and pancreatic cancer;
  • Polyps (gastric and colorectal);
  • Biomarkers (diagnostic and prognostic);
  • Tumor staging;
  • Imaging techniques;
  • Animal models;
  • Stem cells;
  • Advances in chemotherapy;
  • Immunotherapy in gastric and pancreatic cancer, alone or in combination;
  • Advances in the treatment of metastatic pancreatic, CRC and gastric cancer.

We aspire for this Special Issue to cover at least part of the wide spectrum of the etiologies, diagnoses and treatments of these neoplasms, always in the light of a multidisciplinary approach.

Dr. John K. Triantafillidis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastric cancer 
  • colorectal cancer 
  • pancreatic cancer
  • immunotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

19 pages, 2824 KiB  
Article
Regulation of Stemness by NR1D2 in Colorectal Cancer
by Sandra Alonso-García, Paula Sánchez-Uceta, Sara Moreno-SanJuan, Jorge Casado, Jose D. Puentes-Pardo, Huda Khaldy, David Lopez-Pérez, María Sol Zurita-Saavedra, Cristina González-Puga, Angel Carazo and Josefa León
Biomedicines 2025, 13(6), 1500; https://doi.org/10.3390/biomedicines13061500 - 18 Jun 2025
Viewed by 302
Abstract
Background: Nuclear Receptor Subfamily 1 Group D Member 2 (NR1D2), a transcription factor that regulates the circadian clock, has been described as an oncogene in colorectal cancer (CRC). In several types of cancer, NR1D2 regulates cancer progression and relapse through cancer stem [...] Read more.
Background: Nuclear Receptor Subfamily 1 Group D Member 2 (NR1D2), a transcription factor that regulates the circadian clock, has been described as an oncogene in colorectal cancer (CRC). In several types of cancer, NR1D2 regulates cancer progression and relapse through cancer stem cells (CSCs), although this aspect has not been studied in CRC. On the other hand, p53 is a tumour suppressor gene that appears mutated in approximately a 50% CRCs. Interestingly, p53 is considered to be a crucial nexus between circadian clock deregulation and cancer. In addition, p53 regulates CSC phenotypes. Methods: We developed an in vitro model in which NR1D2 was silenced in three isogenic cell lines with different p53 status. In addition, we analysed the expression of NR1D2 in a cohort of patients and determined its relationship with the characteristics of patients and tumours. Results: In the in vitro model, NRID2 silencing reduces cell growth and decreases stemness, although only in cells harbouring a wild type p53. In contrast, in cells lacking a functional p53 or harbouring a mutated one, NR1D2 knockout increases cell growth and stemness. In patients, NR1D2 expression correlates with poorly differentiated tumours and high expression of CSCs markers, although only in tumours with a wild type p53, corroborating the results obtained in the in vitro model. Conclusions: Although more research is needed to analyse the mechanism by which NR1D2 regulates stemness in a p53-dependent manner, our results highlight the possibility of using NR1D2 antagonists for treating this type of patient and to develop personalised medicine. Full article
(This article belongs to the Special Issue New Insights in Gastric, Colorectal, and Pancreatic Cancer)
►▼ Show Figures

Figure 1

16 pages, 3331 KiB  
Article
Utility of Radiological Follow Up of Main-Duct Intraductal Papillary Mucinous Neoplasms and Mixed-Type Intraductal Papillary Mucinous Neoplasms
by Roie Tzadok, Rivka Kessner, Einat Ritter, Asaf Aizic, Hila Yashar, Sapir Lazar, Yuval Katz, Zur Ronen-Amsalem, Arthur Chernomorets, Oren Shibolet and Dana Ben-Ami Shor
Biomedicines 2024, 12(7), 1437; https://doi.org/10.3390/biomedicines12071437 - 27 Jun 2024
Viewed by 1345
Abstract
Background: Intraductal papillary mucinous neoplasms (IPMNs) have the potential to evolve into pancreatic adenocarcinoma (PDAC). While main-duct IPMNs (MD-IPMNs), involving the main pancreatic duct (MPD), are less common than side-branch IPMNs (SB-IPMNs) or mixed-type IPMNs (mixed-IPMNs), their malignant transformation potential is far greater. [...] Read more.
Background: Intraductal papillary mucinous neoplasms (IPMNs) have the potential to evolve into pancreatic adenocarcinoma (PDAC). While main-duct IPMNs (MD-IPMNs), involving the main pancreatic duct (MPD), are less common than side-branch IPMNs (SB-IPMNs) or mixed-type IPMNs (mixed-IPMNs), their malignant transformation potential is far greater. Controversy exists between different guidelines in terms of recommended management strategies. This study was aimed at assessing the utility of the radiological follow up of MD-IPMNs and mixed-type IPMNs, including prevalence of worrisome radiological findings as well as clinical and laboratory parameters, and their correlation with the development of progression or pancreatic adenocarcinoma. Methods: Eighty-four patients with MD-IPMNs or mixed-type IPMNs who underwent at least one magnetic resonance cholangiopancreatography (MRCP) were included. Clinical and laboratory data were obtained retrospectively. A cross-sectional analysis was carried out to establish clinical and laboratory parameters associated with development of PDAC. A retrospective cohort analysis was performed on 44 patients who had at least six months of follow up, trying to identify factors correlating with worrisome radiological features. Results: Nine cases (10.7%) of PDAC were recorded in this cohort. The laboratory and imaging factors associated with cyst size progression greater than 5 mm during follow up were elevated alanine transaminase (ALT) levels, the maximal cyst size, and the MPD diameter. Cross-sectional analysis indicated that PDAC was associated with nausea (p = 0.01), as well as increased levels of aspartate aminotransferase (AST) (p = 0.05), gamma glutamyl transpeptidase (GGT) (p = 0.01), and alkaline phosphatase (ALP) (p = 0.01). Conclusions: Elevated levels of liver enzymes were associated with IPMN progression and, subsequently, the development of PDAC. ALT levels, maximal cyst size, and MPD diameter are associated with the progression of cyst size. These data may aid in risk-stratifying patients when determining the follow up approach for IPMNs. Full article
(This article belongs to the Special Issue New Insights in Gastric, Colorectal, and Pancreatic Cancer)
►▼ Show Figures

Figure 1

Other

Jump to: Research

18 pages, 686 KiB  
Systematic Review
Immunonutrition in Operated-on Gastric Cancer Patients: An Update
by John K. Triantafillidis and Konstantinos Malgarinos
Biomedicines 2024, 12(12), 2876; https://doi.org/10.3390/biomedicines12122876 - 18 Dec 2024
Viewed by 1508
Abstract
Enteral immune nutrition has attracted considerable attention over the past few years regarding its perioperative role in patients undergoing major surgery for digestive cancer. Today, the term enteral immune nutrition refers to the perioperative administration of nutritional preparations containing, among others, specific ingredients [...] Read more.
Enteral immune nutrition has attracted considerable attention over the past few years regarding its perioperative role in patients undergoing major surgery for digestive cancer. Today, the term enteral immune nutrition refers to the perioperative administration of nutritional preparations containing, among others, specific ingredients such as glutamine, omega-3 polyunsaturated fatty acids, and arginine. They provide nutritional support and exert pharmacological effects through the substances contained in these preparations. Their administration to patients with gastric cancer is necessary as malnutrition and other metabolic disorders are frequent symptoms with effects on the level of immune responses, affecting the function of intestinal permeability and, therefore, the effectiveness of chemotherapy. Existing clinical data and data from all meta-analyses published so far support the view that enteral immune nutrition enhances the immune responses of gastric cancer patients, and reduces the rate of postoperative complications, and the duration of hospitalization without, however, improving patient survival. The content of enteral immune nutrition, dose, administration interval, and the effect on patient survival should be more precisely determined through relevant extensive multicenter studies. This systematic review describes and analyses the clinical results and the findings of relevant meta-analyses of the application of enteral immune nutrition in gastric cancer patients, emphasize the importance of this therapeutic intervention for disease progression, and attempts to provide practical guidelines for applying enteral immune nutrition in daily clinical practice. Full article
(This article belongs to the Special Issue New Insights in Gastric, Colorectal, and Pancreatic Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop